HMGB3 and breast carcinoma: In conclusion, this study demonstrated that exosome-mediated transfer of OIP5-AS1 partially induced trastuzumab resistance in breast cancer through miR-381-3p/HMGB3 axis, indicating a therapeutic strategy for the trastuzumab resistance in patients with breast cancer.